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The complexation of 3-alkylcarbonyloxy-7-bromo-5-(2'-chloro)phenyl-1,2-dihydro-3Н-1,4-ben-
zodiazepine-2-ones (R=Ме (1), R=t-Bu (2)) with the central benzodiazepine receptors (CBDR) at 
six temperatures within the range of 0-35°С has been studied by the radioligand analysis method. 
It has been found that formation of the supramolecular complex of compound 1 with CBDR is 
endothermic with a rather great and unfavourable change of enthalpy (∆Н1° = +32,3 kJ/mоl), 
which is compensated by signiﬁ cant change in entropy (∆S1° = +266,7 J/(mоl×К)). On the 
contrary, the binding of compound 2 to CBDR is exothermic (∆Н2° = -20,7 kJ/mоl) and with a 
favourable entropy change (∆S2° = +90,4 J/(mоl×К)). The ester carbonyl groups in compounds 
1 and 2 are also supposed to form different hydrogen bonds with the receptor.
ТЕРМОДИНАМІКА КОМПЛЕКСОУТВОРЕННЯ ЕСТЕРІВ 3-ГІДРОКСИ-7-БРОМ-5-(2'-ХЛОР)ФЕ-
НІЛ-1,2-ДИГІДРО-3H-1,4-БЕНЗОДІАЗЕПІН-2-ОНІВ З ЦЕНТРАЛЬНИМИ БЕНЗДІАЗЕПІНОВИМИ 
РЕЦЕПТОРАМИ
С.П.Смульський, Н.О.Буренкова, С.А.Андронаті, В.І.Павловський, П.Г.Поліщук, К.С.Андронаті
Методом радіолігандного аналізу вивчено комплексоутворення 3-алкілкарбонілокси-
7-бром-5-(2'-хлор)феніл-1,2-дигідро-3Н-1,4-бенздіазепін-2-онів (R=алкіл R=Ме (1), R=t-Bu 
(2)) з центральними бенздіазепіновими рецепторами (ЦБДР) при шести температу-
рах у інтервалі 0-35°С. Встановлено, що утворення супрамолекулярного комплексу 
сполуки 1 з ЦБДР ендотермічне з доволі великою та несприятливою зміною ентальпії 
(∆Н1°=32,3 кДж/моль), яка компенсується значною зміною ентропії (∆S1°=266,7 Дж/(моль×К)). 
Зв’язування сполуки 2 з ЦБДР екзотермічне (∆Н2°=-20,7 кДж/моль) зі сприятливою змі-
ною ентропії (∆S2°=90,4 Дж/(моль×К)). Передбачається також, що естерні карбонільні 
групи у сполуках 1 і 2 утворюють різні водневі зв’язки з рецептором.
ТЕРМОДИНАМИКА КОМПЛЕКСООБРАЗОВАНИЯ ЭФИРОВ 3-ГИДРОКСИ-7-БРОМ-5-(2'-ХЛОР)
ФЕНИЛ-1,2-ДИГИДРО-3H-1,4-БЕНЗОДИАЗЕПИН-2-ОНОВ С ЦЕНТРАЛЬНЫМИ БЕНЗДИАЗЕ-
ПИНОВЫМИ РЕЦЕПТОРАМИ
С.П.Смульский, Н.А.Буренкова, С.А.Андронати, В.И.Павловский, П.Г.Полищук, К.С.Андронати
Методом радиолигандного анализа изучено комплексообразование 3-алкилкарбонил-
окси-7-бром-5-(2'-хлор)фенил-1,2-дигидро-3Н-1,4-бенздиазепин-2-онов R=Ме (1), R=t-Bu 
(2)) с центральными бенздиазепиновыми рецепторами (ЦБДР) при шести температу-
рах в интервале 0-35°С. Обнаружено, что образование супрамолекулярного комплекса 
соединения 1 с ЦБДР эндотермическое с довольно большим и неблагоприятным из-
менением энтальпии (∆Н1°=32,3 кДж/моль), которое компенсировано значительным 
изменением энтропии (∆S1°=266,7 Дж/(моль×К)). Связывание соединения 2 с ЦБДР 
экзотермическое (∆Н2°=-20,7 кДж/моль) и с благоприятным изменением энтропии 
(∆S2°=90,4 Дж/(моль×К)). Предполагается также, что сложноэфирные карбонильные 
группы в соединениях 1 и 2 образуют различные водородные связи с рецептором.
Analysis of equilibrium formation of supramolecu-
lar complexes of drugs with membrane receptors within 
range from 0 to 35°C temperature led to certain genera-
lizations. For the majority of membrane receptors, it 
was found ability for thermodynamic discrimination 
of ligands as agonists and antagonists. For 184 inde-
pendent experiments and 10 receptor systems the phe-
nomenon of enthalpy-entropy compensation was de-
scribed [1]. The majority of membrane receptors form 
supramolecular complexes with drugs and endogenous 
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ligands (neurotransmitters) with the temperature in-
dependent enthalpies (∆H) and entropies (∆S) [2].
Information obtained on the basis of thermody-
namic analysis of ligand receptors binding is unique 
and is not available if equilibrium constants are mea-
sured at one temperature. Cautious interpretation 
of thermodynamic analysis results allows conclud-
ing on the mechanism of complexation and the na-
ture of intermolecular interactions between a ligand 
and a receptor in supramolecular complexes, as well 
as on  the causes of intrinsic activity [2, 3].
Analysis of the binding in dependence of tempe-
rature allows determining free energies and, conse-
quently, the equilibrium constants at different tem-
peratures within a given range (typically from 0 to 
35°C), including the constant at body temperature, 
what is the closest approximation to the conditions 
of pharmacological tests in experimental animals.
The van’t Hoff equation is used in the thermody-
namic analysis 
lnKА = -∆Н°/RT + ∆S°/R,
where R – gas constant; T – temperature in Kelvin; 
KA – equilibrium association constant of ligand-re-
ceptor complex; ∆Н° and ∆S° are standard enthalpy 
and entropy of complexation, respectively. The tem-
perature of 298,15 K (25°C) and atmospheric pres-
sure are the standard conditions as a rule.
GABAA receptor-ionophoric complex belongs to 
the superfamily of ionotropic receptors and provides 
the Cl¯ and HCO3¯ ion transport into the cell. In ad-
dition to the GABA binding sites, GABAA
 ionophoric 
complex includes binding sites of benzodiazepines, 
picrotoksinin, β-carbolines, barbiturates, and other li-
gands [4]. 1,4-Benzodiazepine derivatives are the most 
common and known ligands of the central benzodi-
azepine receptors and are widely used as medicine 
neurotropic drugs [4, 5]. Thermodynamic analysis of 
binding of drugs of benzodiazepine series (diazepam, 
clonazepam, alprazolam and others) with CBDR is 
described in [6-13], and results of studies [6-12], are 
summarized in the review [3]. The van’t Hoff plots of 
the ln(1/Ki) versus the (1/T)×(1000/K) for all ben-
zodiazepines described in the literature are linear 
within the temperature range from 0 to 35°C, with 
the exception of certain cases, when broken lines of 
plots for clonazepam at 21°C [8] and #lunitrazepam 
at 10°C were observed [9]. All 1,4 benzodiazepines 
described in the literature [6-13], with the exception for 
triazolam and dezmethylmedazepam, form exother-
mic complexes with CBDR. It is known from the lit-
erature that changes in the benzodiazepine chemical 
structure ambiguously affect the free energy (∆Н° 
and ∆S°) of the complexation with CBDR. For example, 
molecules of alprazolam and triazolam differ by a chlo-
rine atom in 2 position of 5-phenyl radical, while the 
thermodynamic pro#iles of their interaction with CBDR 
are diametrically opposed. Alprazolam, containing no 
chlorine atom in the 5-phenyl radical, forms an exo-
thermic complex with CBDR, and triazolam, which 
contains a chlorine atom in this position, forms an 
endothermic complex with the CBDR [10]. At the 
same time, #lunitrazenpam, diazepam and nordiaze-
pam not only have close values of free binding ener-
gies at 37°C (∆G°= -48±6, -45±5, -41±4 kJ/mоl), but 
also relatively close values of enthalpy (∆Н°=-53±3, 
-41±2, -44±7 kJ/mоl) and entropy (Т∆S°=-5±7, +5±5, 
-3±8 kJ/mоl) members of free energies [9].
Currently, there are no systematic data of studies 
on the relationship between the chemical structure 
of the 1,4-benzodiazepines, the degree of activation 
of GABAA receptor complex and the structures of free 
energies (∆Н°, ∆S°) of their complexation with CBDR. 
There are no works on the thermodynamic analysis 
of complexation of substituted in the third position 
1,4-benzodiazepines with CBDR, despite the fact that 
this series of derivatives is very promising concern-
ing the search for new neurotrophic drugs. There are 
well known drugs among the representatives of this 
series of compounds: lorazepam, oxazepam, temaze-
pam, and others. For a long period of time we carry 
out research in molecular design, synthesis and study 
of relationship of structure – properties, mode of action 
and pharmacology of 1,4-benzodiazepine-2-one de-
rivatives [14-19]. Af#inity and selectivity for central 
and peripheral benzodiazepine CNS receptors at the 
0°С was examined for many compounds by radioli-
gand analysis [17, 20-26]. However, information ob-
tained at the same temperature is insuf#icient and 
doesn’t allow making a decision about driving forces 
of complexation and nature of interactions with CBDR 
of the investigated 1,4-benzodiazepines. Thereby (and 
in continuation of our ongoing research), it was in-
teresting to investigate thermodynamics of comple-
xation of 3-substituted 1,4-benzodiazepin-2-ones (com-
Fig. 1. The van’t Hoff plots showing the affect of temperature on the 
association constants (1/Ki) of compounds 1, 2 in the experiment 
on the displacement of [3H] fl umazenil. Values 1/Ki are mean of four 
independent determinations, each performed in triplicate. Linear 
interpolation over the points connected by the continuous line 
(0≤t≤35 C) gives correlation coeffi cients, r, in the range of 0.98-0.99.
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pounds 1 and 2, Fig. 1, Scheme 1) with CBDR. The 
compounds for which the thermodynamics of bind-
ing to the GABAA receptor complex have been stud-
ied in this paper have highly anxiolytic, anticonvul-
sant and sedative activity and high afinity for CBDR 
[24]. In this paper, compounds 1 and 2 as research 
objects were used.
Results and Discussion
The table contains inhibition constants (Ki) for 
the compounds 1 and 2 at six temperatures 0, 10, 
20, 25, 30 and 35°C, as well as, calculated on the 
base of van’t Hoff plots standard enthalpies (∆H°) 
and entropies (∆S°) for equilibrium displacement of 
[3H]lumazenil from speciic binding sites of CBDR. 
The table shows also dissociation constants for [3H]
lumazenil complex with CBDR, which were used by 
us for the calculation of Ki for compounds 1 and 2 
by the Cheng-Prusoff equation. The van’t Hoff plots 
for compounds 1 and 2, in the studied temperature 
range, were strictly linear (Fig. 1).
The binding of compound 1 to the CBDR of the 
rats cerebral cortex was accompanied by heat ab-
sorption (∆Н°1 = +32,3 kJ/mоl) and relatively large 
increase in entropy (∆S°1 = +266,7 J/(mоl×К)). While 
the compound 2 complexation with CBDR was exother-
mic (∆Н°2 = -20,7 kJ/mоl and ∆S°2 = +90,4 J/(mоl×К)), 
and was accompanied with temperature increase 
which was two-fold lesser. Thus, complexation of 
compounds 1 and 2 with CBDR are driven by differ-
ent forces. Thus, the compound 1 complexation with 
the receptor is exclusively driven by entropy, while 
the compound 2 binding to the receptor is driven by 
both enthalpy and entropy.
A well-known generalized model of the receptor 
complex with benzodiazepines of Huang Q. et al. [27] 
suggests the following features of the molecular in-
teraction of 1,4-benzodiazepine-2-ones with CBDR. 
Carbonyl oxygen of the amide group and nitrogen 
atom N4 of diazepine ring form hydrogen bonds with 
the receptor site. Benzene ring in position 5 and the 
ring condensed with 1,4-diazepine cycle, as well as 
substituents in position 7, interact with the hydro-
phobic centers of the receptor site. Taking into ac-
count the given model, and keeping in mind the ac-
ceptor properties of the ester carbonyl groups (the 
substituents in position 3 of compounds 1 and 2), one 
can assume the formation of different hydrogen bonds 
with donor regions of CBDR sites (Fig. 2), weak hy-
drogen bond with the receptor for the compound 1, 
and stronger one in the case of compound 2. It is 
Table 
Equilibrium inhibition constants (Ki), dissociation constants (KD) at various temperatures, 
standard enthalpies (∆H°) and entropies (∆S°) for complexation 
of the compounds 1-4 and [3H]! umazenil with CBDR
Compounds
Ki±SEM [nM] ∆Н°±SEM
(kJ/mol)
∆S°±SEM
(J/(mоl×К))0°С 10°С 20°С 25°С 30°С 35°С
1
16,50
(1,2)
11,80
(1,1)
6,05
(0,4)
6,21
(0,3)
4,56
(0,2)
3,13
(0,1)
+32,3
(3,0)
+266,7
(10)
2
1,91
(0,04)
3,19
(0,15)
3,91
(0,1)
4,19
(0,3)
5,00
(0,2)
5,83
(0,4)
-20,7
(2)
+90,4
(6)
3* +35,1 +305,0
4* +23,4 +191,6
[3H]Flu-mazenil**
KD±SEM [nM]
1,23
(0,05)
2,3
(0,1)
3,2
(0,1)
4,00
(0,2)
4,90
(0,2)
6,30
(0,5)
* Data taken from ref. [10]; ** Data taken from ref. [33]
Fig. 2. Hypothetical scheme of interactions of compounds 1 and 2 
with hydrophobic sites and donor sites of hydrogen bonds (indicated 
by dotted lines) of CBDR site (based on Huang Q model) [30].Scheme 1
Журнал органічної та фармацевтичної хімії. – 2012. – Т. 10, вип. 4 (40)
68
possible that formation of the hydrogen bonds can 
occur either competing for the donor centers of the 
receptor with nitrogen atoms N4 or amide carbonyl 
groups of the 1,4-benzodiazepine ring or by the for-
mation of new additional hydrogen bonds with do-
nor sites of CBDR. In any case, thermodynamic pro-
iles of these compounds complexation with the re-
ceptor give indirect evidence in favour of the offered 
assumption (Table and Fig. 3). It is generally accept-
ed, that hydrogen bonds formation is accompanied 
by decrease of enthalpy and entropy. Therefore, in 
whole energetic balance (change in free energy), strong 
hydrogen bonds may exceed energy of non-speciic 
(hydrophobic) interactions, and that often  leads to 
decrease of the process enthalpy and minor posi-
tive changes in entropy, and in some cases, to its 
decrease. Weak hydrogen bonds, which are accom-
panied with insigniicant decrease of enthalpy, in many 
cases, aren’t able to exceed positive change of enthal-
py of non-speciic hydrophobic interaction of ligand 
with its receptor. As a result, change of complexation 
enthalpy may turn out to be a positive one. However, 
it is arise of question how to explain the fact that 
hydrogen bond in the case of compound 1 (R = Me) 
is weaker then hydrogen bond of compound 2 (R = 
t-Bu) when they interact with their receptors.
Unfortunately, the involvement of a methyl group 
(compound 1) and tert-butyl group (compound 2) 
in interaction with CBDR can not be described with-
in the model of Huang Q. et al. [27], because substi-
tuted in the 3 position of 1,4-benzodiazepines are 
not taken into account at creation of this model.
According to the results of our long-term research 
[28], pharmacological activity of 3-alkyl-substituted 
(alkyl = Me, Et, i-Pr and t-Bu) 1,4-benzodiazepines is 
inversely related to lipophilicity. Taking into account 
these indirect facts and thermodynamic analysis con-
ducted by us on the binding of the compounds 1 and 
2 with CBDR, it could be assumed that the t-Bu radical 
of the compound 2 does not enter into hydrophobic 
interactions with the receptor. The thermodynamic 
profiles of the interaction of compounds 1 and 2 
with benzodiazepine receptor (∆Н°1 = +32,3 kJ/mоl, 
∆S°1 = +266,7 J/(mоl×К), ∆Н°2 = -20,7 kJ/mоl, ∆S°2 
= +90,4 J/(mоl×К)) prove this fact. It is seen in the 
coordinates -T∆S° versus ∆Н° (Fig. 3) that the driv-
ing forces for the complexation of compound 2 with 
CBDR are changes in enthalpy (∆Н°) and entropy (∆S°). 
Compound 1, in contrast to compound 2, binds to 
the receptor due to the entropy change only.
There are at least two examples in the literature 
where the driving force of benzodiazepine comple-
xation with CBDR is the change in entropy. These com-
pounds are triazolam (3) and dezmethylmedazepam 
(4), the thermodynamic analysis of the binding of which 
was carried out under conditions similar to conditions 
of our experiments (on the twice washed membranes 
in the presence of 0,2 M NaCl in the incubation me-
dium) [10]. Thus, the compounds 1, 3 and 4 form a 
ligand group, which binding with CBDR differs signi-
icantly from those described in the literature and ben-
zodiazepines  studied by us (compound 2) (Scheme 2).
Thermodynamic analysis of complexation of com-
pounds 1, 3 and 4 with CBDR has demonstrated that:
1) compounds 1, 3 and 4 bind to CBDR with the 
heat absorption and a large favorable change in en-
tropy (see Table). This means that their interaction 
with the receptor is mainly caused by the rearrange-
ment of solvent molecules near the receptor site and 
near the interacting ligand molecules. It is generally 
accepted that such complexation thermodynamic pro-
ile mainly is a result of hydrophobic ligand-receptor 
interactions [29]:
2) unlike the compound 1, the compound 2 (just 
as benzodiazepines described in literature [6-13], 
with the exception of the compounds 3 and 4) forms 
exotermic complex with CBDR.
It is known not only numerous multi-center re-
lationships and interactions, but also the reorgani-
zation of a solvent contribute to the free energy of 
ligand-protein (receptor) complexation. It is consid-
ered that the only theoretical calculation is able to dif-
ferentiate these contributions and to correlate them 
with structural fragments of molecules of ligands and 
receptors [30, 31].Our results on the thermodynam-
ics of binding of the esters (compounds 1 and 2) to 
CBDR, as well as literature data, for example [10], on 
Fig. 3. Represent the thermodynamic data of the interaction of 
compound 1 (●) and 2 (▲) with CBDR in the coordinated -TDS° 
versus ∆Н° (were KA=10
4 M-1 and KA=10
11 M-1 are lower and upper 
limits of values of association constants of the drugs, respectively, 
with bioreceptors, see ref. 1).
Scheme 2
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the binding of alprazolam, triazolam and dezmethyl-
medazepam to benzodiazepine receptors demonstra-
te that the thermodynamics of the formation of supramo-
lecular ligand-CBDR complexes can be extremely sen-
sitive to changes in the ligand chemical structure.
Changes of standard entropies of complexation 
of compounds 1, 3, 4 allow supposing that the rear-
rangement of solvent molecules is the main reason 
for the change of the free energies of complexation 
of these compounds with CBDR and it demonstrates 
that the thermodynamics of the formation of supra-
molecular ligand-CBDR complexes can be extremely 
sensitive to changes in the ligand chemical structure. 
There is no yet satisfactory explanation of the fact 
concerning the dominant participation of nonspeci-
!ic interactions of the studied compound 1 as com-
pared to compound 2, at the formation of complex 
with benzodiazepine receptors. These differences are 
dif!icult to explain without pharmacophore-recep-
tor models for 3-substituted 1,4-benzodiazepines. We 
hope that further investigation of thermodynamics 
of complexation in the series of 3-substituted 1,4-ben-
zodiazepines with CBDR will contribute to the clari-
!ication of this interesting fact and may be used in 
the further development of models of the complex 
1,4-benzodiazepin – CBDR.
Experimental part
Compounds 1-2 were synthesized using litera-
ture procedures [32].
In vitro receptor binding assays. [3H]Flumaze-
nil binding
Adult male Wistar rats with a body weight of 180-
220 g were maintained under an arti!icial 12-h-light/dark 
cycle (light on 08.00 to 20.00 h). Food and water were 
freely available until the time of the experiment. An-
imal care and handling throughout the experimental 
procedures were in accordance with the European 
Communities Council Directive of 24 November 1986 
(86/609/EEC). The experimental protocols were ap-
proved by the Animal Ethical Committee of the Uni-
versity of Cagliari. Af!inity of compounds 1, 2 for CBDR 
of rat brain was determined by modified method 
and values of ІС50 were evaluated.
Animals were anesthetized and decapitated, the 
cerebral cortex was quickly extracted and homoge-
nized in 30 ml of 0,05 M ice-cold citrate buffer (pH 7,1 
at 4°С) with a Dounce homogenizer. The homogen-
ate was centrifuged at 20 000 g for 15 min at 4°С. 
The pellet was resuspended in initial volume of the 
same buffer and centrifuged again under the same 
conditions. The process of homogenization and cen-
trifugation was repeated for 2 times. Supernatant was 
decanted, the residue was resuspended in 0,05 M of 
ice-cold incubation citrate buffer containing 200 mM 
NaCl to obtain the suspension with wet membrane con-
centration of 50 mg/ml and adjusted for each tem-
perature.
Thermodynamic analysis of the formation of com-
plexes of compounds 1, 2 with CBDR was carried out at 
temperatures of 0, 10, 20, 25, 30 and 35°C. Determi-
nation of equilibrium binding constants (KA = 1/Ki) 
for the binding of compounds 1, 2 to membrane com-
plex of the rats cerebral cortex was carried out in 
0,5 cm3 of tris-citrate incubation buffer pH 7,1, ad-
justed for each temperature. The incubation time 
ranged from 75 min at 0°C to 20 min at 35°C [33]. 
Nonspeci!ic binding (which was no more than 10%) 
of the radioligand [3H] !lumazenil ([3H]Ro15-1788) 
was determined in the presence of 1×10-6mol/dm3 
cold flumazenil. To determine the semi-inhibitory 
concentrations (IC50) for the compounds 1, 2 eight 
concentrations were used for each compound, rang-
ing from 0,1×10-9 to 1×10-6×mol/dm3. Inhibition con-
stant Ki was calculated using the Cheng-Prusoff for-
mula (Ki = IC50/(1+[L]/KD)) [34], where IC50 – con-
centration of test ligand at which is observed 50% 
radioligand displacement from speci!ic binding sites 
of the receptor, [L] – total concentration of radioli-
gand, KD – dissociation constant of the radioligand 
complex with the CBDR for each of the experimental 
temperatures, taken from [33]. The standard free ener-
gies (∆G°) of compounds 1, 2 complexation were calcu-
lated by the equation of van’t Hoff (∆G° = -RTln(1/Ki)). 
The standard enthalpy (∆Н°) and entropy (∆S°) of 
complexation were obtained by regression analysis 
from the slope of the van’t Hoff plots (-∆Н°/RT) and 
the intersection plots (-∆S°/R) with the ordinate axis, 
where T = 298,15 K, R = 8,314 J/(mol×K).
Conclusion
1. Enthalpy and entropy of the compounds 1 and 
2 complaxetion are more sensitive to changes in their 
chemical structure, than free energy.
2. Driving forces of complexation of the compounds 
1 and 2 with CBDR are different. The compound 1 
binds to receptor solely due to the changes in both 
enthalpy and entropy.
3. It is suggested that the compounds 1 and 2 form 
different in respect to energy hydrogen bonds with 
the receptor.
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